Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Amvuttra (vutrisiran) for review to treat ATTR ...
Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...
Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...
We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...
Use the least expensive option of the available treatments (including eplontersen and vutrisiran). Take account of administration costs, dosages, price per dose and commercial arrangements. If the ...
The FDA’s acceptance of the supplemental New Drug Application for vutrisiran in treating TTR amyloidosis cardiomyopathy is a positive development. However, the absence of an advisory committee ...
Another player in this space is Alnylam which has developed an RNA silencing therapy Amvuttra (vutrisiran) for people with ATTR-CM, which had very good phase 3 results published earlier this year. The ...
If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback